A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

NCT03100500 | Completed Phase 3 Results

• 1 other identifier: CQVM149B1305
• Study Type: interventional
• Target: 51
• Locations: 1 country
• Sites: 15

Brief Summary

The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.

Conditions

Asthma

Keywords

QVM149,; Asthma,; Japanese,; Allergic asthma,; Allergy triggered asthma,; Reactive asthma,; Asthma attack,; Difficulty breathing

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  A TEAE is any adverse event that started on or after the time of the first inhalation of study drug but not later than 7 days (30 days in the case of a SAE) after the last administration. A SAE is described as any adverse event that leads to death, is life-threatening, results in persistent or significant disability/incapacity, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event which is medically significant.

  Up to 52 weeks

Secondary Outcomes (5)

• Change From Baseline of Pre-Dose Forced Expiratory Volume in 1 Second (FEV1) Measured After 26 And 52 Weeks Treatment

  Baseline, Weeks 26 and 52

• Change From Baseline of Morning and Evening Peak Expiratory Flow (PEF) During 52 Weeks Treatment

  Baseline up to Week 52

• Change From Baseline of Asthma Control Questionnaire (ACQ-7) After 26 And 52 Weeks Treatment

  Baseline, Weeks 26 and 52

• Responder Rate of Participants Achieving the Minimal Important Difference (MID) of ACQ-7 ≥ 0.5 After 26 And 52 Weeks Treatment

  Weeks 26 and 52

• Change From Baseline of Rescue Medication Use During 52 Weeks Treatment

  Baseline up to Week 52

Study Arms (1)

QMF149

EXPERIMENTAL

All eligible patients take QMF149 150/320 μg once daily over 52 weeks.

Drug: QMF149

Interventions

QMF149 DRUG

QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler

QMF149

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent must be obtained before any assessment is performed.
• Male and female adult patient ≥ 18 years old.
• Patients with a diagnosis of persistent asthma for a period of at least 1 year prior to Visit 1.
• Patients who have used medium or high dose inhaled corticosteroids (ICS) plus at least 1 controller for asthma for at least 3 months and at stable dose and regimen for at least 4 weeks prior to Visit 1.
• Patients must have Asthma Control Questionnaire-7 (ACQ-7) score ≥ 1.5 at Visits 2 and qualify for treatment with high dose ICS/long-acting β2 agonist (LABA).
• Pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) of ≥ 50% and ≤ 85% of the predicted normal value for the patient after withholding bronchodilators at Visit 2.
• Repeating is allowed once only. Repeating of percentage predicted FEV1 should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before Visit 99.
• Patients must demonstrate reversibility defined as an increase in FEV1 of ≥ 12% and 200 mL within 15 to 30 minutes after administration of 400 µg of salbutamol at Visit 2. Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing.
• If reversibility is not proven at Visit 2, patients may be permitted to enter the study with historical evidence of reversibility that was performed within 5 years prior to Visit 1.
• Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test (defined as a provoked fall in FEV1 of 20% by bronchoconstriction agent e.g., methacholine, histamine) or equivalent test (e.g., astography) that was performed within 5 years prior to Visit 1.
• Where patient is assessed as eligible based on historical evidence, a copy of the original printed report must be available as source documentation.
• If reversibility is not proven at Visit 2 and historical data is not available, reversibility should be repeated once in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day).
• If reversibility is not demonstrated at Visit 2 (or after repeated assessment at ad-hoc visit) and historical evidence of reversibility/bronchoprovocation/astography is not available, patients must be screen failed.

You may not qualify if:

• Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1.
• Patients who have ever required intubation for a severe asthma attack/exacerbation.
• Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.
• Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 99. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.
• Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
• Patients with severe narcolepsy and/or insomnia.
• Pregnant or nursing (lactating) women.
• Women of child-bearing potential unless they are using highly effective methods of contraception during dosing and for 30 days after stopping of investigational medication.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (15)

Novartis Investigative Site

Nagoya, Aichi-ken, 457-8511, Japan

Location

Novartis Investigative Site

Fukuoka, Fukuoka, 819-8555, Japan

Location

Novartis Investigative Site

Chitose, Hokkaido, 066-0021, Japan

Location

Novartis Investigative Site

Kitahiroshima, Hokkaido, 061-1121, Japan

Location

Novartis Investigative Site

Sapporo, Hokkaido, 006-0811, Japan

Location

Novartis Investigative Site

Sapporo, Hokkaido, 064-0801, Japan

Location

Novartis Investigative Site

Takamatsu, Kagawa-ken, 760-0018, Japan

Location

Novartis Investigative Site

Yokohama, Kanagawa, 223-0059, Japan

Location

Novartis Investigative Site

Yokohama, Kanagawa, 231-8682, Japan

Location

Novartis Investigative Site

Yokosuka, Kanagawa, 239-0821, Japan

Location

Novartis Investigative Site

Chino, Nagano, 391-0011, Japan

Location

Novartis Investigative Site

Higashiosaka, Osaka, 577-0843, Japan

Location

Novartis Investigative Site

Chuo Ku, Tokyo, 103 0027, Japan

Location

Novartis Investigative Site

Chuo-ku, Tokyo, 103-0027, Japan

Location

Novartis Investigative Site

Toshima-ku, Tokyo, 171-0014, Japan

Location

MeSH Terms

Conditions

Asthma; Dyspnea

Interventions

QMF149

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Director
• Organization: Novartis Pharmaceuticals

novartis.email@novartis.com

862-778-8300

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 21, 2017
• First Posted: April 4, 2017
• Study Start: April 25, 2017
• Primary Completion: July 19, 2018
• Study Completion: February 12, 2019
• Last Updated: February 7, 2020
• Results First Posted: February 7, 2020

Record last verified: 2020-01

Data Sharing

• IPD Sharing: Will not share

Locations

JP (15)